TECH
BIO-TECHNE CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 26 to Apr 8 ▼ 2 sells: April McClain Delaney sold $1,001 - $15,000, last disclosed May 7
- May 15 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Jun 11
- Jun 25 ▲ Bio-Techne has entered into a definitive agreement to be acquired by…
- Jun 30 ▲ 16 funds open new positions (13F)
- Aug 10 ▲ Bio-Techne (TECH) filed a preliminary proxy statement (PREM14A) for…
- Aug 12 ▲ Bio-Techne reported Q4 FY2026 results with organic revenue growth of…
- Aug 12 Dividend: Bio-Techne Declares Dividend
- Aug 13 ▼ Wells Fargo downgrades
- Aug 14 ▲ Short interest falls 30.3% to 6.46M
- Sep 23 ▲ Bio-Techne shareholders voted overwhelmingly to approve the acquisit…
- Sep 23 ▲ Bio-Techne shareholders voted to approve the acquisition by Merck KG…
- Nov 4 Dividend: BIO-TECHNE DECLARES DIVIDEND
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Aug 15. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 49 added (16 new), 52 trimmed or exited. Largest new: Millennium Management $69.9M, Tudor Investment Et Al $66.6M.
- Short sellersSTEADY
Short interest +2.0% to 7.70M shares. 2.7 days to cover, ≈4.9% of shares.
- TrendUPTREND
0% above its 50-day average. New closing high $72.84 on Nov 12.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $904.0M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $518.8M |
| MORGAN STANLEY | TRIM | $450.4M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | TRIM | $194.0M |
| JPMORGAN CHASE & CO | ADD | $132.6M |
| Amundi | DOUBLED | $129.1M |
| MAVERICK CAPITAL LTD | TRIM | $108.5M |
| Bank of New York Mellon Corp | TRIM | $90.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is inside the target range. Median implies +0%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 13, 2026 | Wells Fargo DOWNGRADE | Equal-Weight |
| Jul 9, 2026 | RBC Capital DOWNGRADE | Sector Perform |
| Jun 30, 2026 | TD Cowen DOWNGRADE | Hold |
| Jun 30, 2026 | Benchmark DOWNGRADE | Hold |
| Jun 29, 2026 | Citigroup DOWNGRADE | Neutral |
| Jun 26, 2026 | Stephens & Co. DOWNGRADE | Equal-Weight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Hippel James CFO Nov 1, 2026 | EXERCISE | 11,545 sh |
Kelderman Kim Chief Executive Officer Nov 1, 2026 | TAX W/H | $173.3K |
Hippel James CFO Nov 1, 2026 | TAX W/H | $370.3K |
BAUMGARTNER ROBERT V Director Oct 29, 2026 | AWARD | 2,750 sh |
Bushman Julie L Director Oct 29, 2026 | AWARD | 2,750 sh |
Klimovsky Judith V. Director Oct 29, 2026 | AWARD | 2,750 sh |
Herr Amy E. Director Oct 29, 2026 | AWARD | 2,750 sh |
Vessey Rupert Director Oct 29, 2026 | AWARD | 2,750 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 2 press releases · 4 bullish · 1 bearish · 5 neutral- NEUTRAL 10-Q/ANov 12, 2026
Bio-Techne filed this Form 10-Q/A solely to correct the signature page of its original 10-Q for…
This filing is a routine administrative correction with no trading implications. Monitor the pending merger with Merck KGaA for material developments.
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G for Bio-Techne Corp, reporting beneficial…
Fidelity's passive stake remains minimal at 0.7% with a slight increase in share count but unchanged percentage. No material impact expected; monitor for any future conversion to 13D if the position…
- NEUTRAL 8-KNov 3, 2026
Bio-Techne filed an 8-K announcing a quarterly cash dividend of $0.08 per share for the quarter…
The dividend is small and routine; the more significant event is the pending Merck KGaA acquisition, which conditions the dividend payment. Monitor for shareholder vote and regulatory approvals on…
- NEUTRAL PRESS RELEASENov 3, 2026
Bio-Techne declared a quarterly dividend of $0.08 per share, payable November 23, 2026 to holders…
The dividend is routine and small relative to market cap. The pending Merck KGaA acquisition is the key catalyst; monitor for shareholder vote and regulatory approvals.
All TECH filing & press-release reports (12)
- 10-Q/A reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- PRESS-RELEASE reportNov 3, 2026
- 8-K reportNov 3, 2026
- INST-CLUSTER reportOct 29, 2026
- 10-K/A reportOct 28, 2026
- 8-K reportSep 23, 2026
- PRESS-RELEASE reportSep 23, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportAug 12, 2026
- PREM14A reportAug 10, 2026
- DEFA14A reportJun 25, 2026